- VernacularTitle:维莫非尼联合利妥昔单抗成功治疗复发性毛细胞白血病1例
- Author:
Yuchong QIU
1
,
2
,
2
,
3
,
4
;
Meizi LI
2
,
4
,
5
;
Lu ZHANG
1
,
2
,
4
;
Jian LI
1
,
2
,
4
Author Information
- Publication Type:Journal Article
- Keywords: hairy cell leukemia; relapse; BRAF inhibitor; rituximab
- From: JOURNAL OF RARE DISEASES 2025;4(1):106-111
- CountryChina
- Language:Chinese
-
Abstract:
Hairy cell leukemia(HCL) is a rare malignant hematological tumor. This article presents the diagnosis and treatment of a patient with recurrent HCL. This patient, a 51-year-old female, was diagnosed with HCL in June 2013 and subsequently received monotherapy with cladribine. Post-treatment evaluation indicated a partial remission. In November 2023, she experienced chest tightness and shortness of breath with ultrasound revealing a right-sided pleural effusion. A follow-up examination in February 2024 confirmed the relapse of HCL. She was then treated with a combination of vemurafenib and rituximab, which resulted in a rapid complete remission without minimal residual disease. This case provides valuable insights into the management of recurrent HCL.